Evidence map›Paper›PMID 37318058›Full record

ArticleNeuro-oncology2023

PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma.

Sabine Mueller, Cassie Kline, Schuyler Stoller, Shannon Lundy, Lauren Christopher, Alyssa T Reddy, Anu Banerjee, Tabitha M Cooney, Shannon Raber, Carly Hoffman and 10 more

Open access · bronzeAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Protocols and safety profile of convection enhanced delivery in pediatric patients: a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Convection enhanced delivery of Rhenium (Nature communications · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

Sabine MuellerDepartment of Neurology, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-3452-5150
Cassie KlineDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-7765-7690
Schuyler StollerDepartment of Neurology, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-1931-7521
Shannon LundyDepartment of Pediatrics, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0001-9809-1104
Lauren ChristopherDepartment of Pediatrics, University of California, San Francisco, San Francisco, California, USA.
Alyssa T ReddyDepartment of Neurology, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-5052-0501
Anu BanerjeeDepartment of Pediatrics, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-9657-4839
Tabitha M CooneyDepartment of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.
Shannon RaberDepartment of Pediatrics, University of California, San Francisco, San Francisco, California, USA.
Carly HoffmanDepartment of Pediatrics, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0003-0831-4285
Tracy LuksDepartment of Radiology, University of California, San Francisco, San Francisco, California, USA.
Eva Wembacher-SchroederBrainlab AG, Munich, Germany.
Nina LummelBrainlab AG, Munich, Germany.
Yalan ZhangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Erin R BonnerCenter for Genetic Medicine Research, Children's National Medical Center, Washington, DC, USA.
Javad NazarianDepartment of Pediatrics, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-1951-9828
Annette M MolinaroDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-9854-7404
Michael PradosDepartment of Pediatrics, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-9630-2075
Javier E Villanueva-MeyerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-5910-0757
Nalin GuptaDepartment of Pediatrics, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0001-9539-7052
University of California, San Francisco · USBrainlab (Germany) · DEChildren's National · USChildren's Hospital of Philadelphia · USDana-Farber/Boston Children's Cancer and Blood Disorders Center · US

Funding

DIPG Collaborative Foundation MTX110Pediatric Brain Tumor FoundationPNOC FoundationV foundation
6 · The paper itself

Abstract

backgroundThe objective of this study was to determine the safety, tolerability, and distribution of MTX110 (aqueous panobinostat) delivered by convection-enhanced delivery (CED) in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) who completed focal radiation therapy (RT).

methodsPatients with DIPG (2-21 years) were enrolled after RT. CED of MTX110 combined with gadoteridol was completed across 7 dose levels (DL) (30-90 µM; volumes ranging from 3 mL to 2 consecutive doses of 6 mL). An accelerated dose escalation design was used. Distribution of infusate was monitored with real-time MR imaging. Repeat CED was performed every 4-8 weeks. Quality-of-life (QoL) assessments were obtained at baseline, every 3 months on therapy, and end of therapy.

resultsBetween May 2018 and March 2020, 7 patients who received a total of 48 CED infusions, were enrolled (median age 8 years, range 5-21). Three patients experienced dose-limited toxicities. Four grade 3 treatment-related adverse events were observed. Most toxicities were transient new or worsening neurologic function. Median overall survival (OS) was 26.1 months (95% confidence interval: 14.8-not reached). Progression-free survival was 4-14 months (median, 7). Cumulative percentage of tumor coverage for combined CED infusions per patient ranged from 35.6% to 81.0%. Increased CED infusions were negatively associated with self-reported QoL assessments.

conclusionRepeat CED of MTX110 with real-time imaging with gadoteridol is tolerable for patients with DIPG. Median OS of 26.1 months compares favorably with historical data for children with DIPG. The results support further investigation of this strategy in a larger cohort.

Indexed as

Antineoplastic AgentsBrain Stem NeoplasmsDiffuse Intrinsic Pontine GliomaGliomaAdolescentAdultChildChild, PreschoolConvectionGadoliniumHeterocyclic CompoundsHistone Deacetylase InhibitorsHumansOrganometallic CompoundsPanobinostatQuality of LifeAntineoplastic AgentsGadoliniumgadoteridolHeterocyclic CompoundsHistone Deacetylase InhibitorsOrganometallic CompoundsPanobinostatConvection-enhanced deliveryDIPGMTX110real-time imaging monitoring

Identifiers

PMID37318058
PMCPMC10628948
OpenAlexW4380730469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.